Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations
暂无分享,去创建一个
[1] S. Frost,et al. Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection , 2000, Journal of Virology.
[2] M. Youle,et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.
[3] Vincent C. Emery,et al. The Dynamics of Human Cytomegalovirus Replication in Vivo , 1999, The Journal of experimental medicine.
[4] H. Mitsuya,et al. Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay , 1999, Journal of Virology.
[5] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[6] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[7] John M. Leonard,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.
[8] D. Venzon,et al. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. , 1998, The Journal of infectious diseases.
[9] P. Harrigan,et al. Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro , 1998, Journal of Virology.
[10] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[11] R de Boer,et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.
[12] R. Brettle,et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals , 1997, The Lancet.
[13] D. Lamarre,et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.
[14] H. B. Schock,et al. Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.
[15] W. Keulen,et al. Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.
[16] A S Perelson,et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.
[17] D. Richman. Clinical significance of drug resistance in human immunodeficiency virus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[19] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[20] B. Larder,et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.
[21] J. Holland,et al. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses , 1991, Journal of virology.
[22] M. Wainberg,et al. Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy. , 1992, Cancer investigation.